These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2178666)

  • 1. Anti-tumour efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cells.
    Okada T; Higuchi M; Takano M; Maruyama T; Imai Y; Osawa T
    Br J Cancer; 1990 Feb; 61(2):241-9. PubMed ID: 2178666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo localization of antitumor lymphocytes separated with Dolichos biflorus lectin.
    Okada T; Imai Y; Osawa T
    Immunol Lett; 1990 Jun; 24(3):185-90. PubMed ID: 2384261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
    Okada T; Ezawa K; Imai Y; Osawa T
    Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
    Urano K; Habu S; Nishimura T
    Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-metastatic effect by in vivo administration of concanavalin A through augmentation of T-derived activated killer activity: efficacy to B16 melanoma expressed MHC antigen.
    Taniguchi K; Kawano YI; Toshitani A; Karashima A; Nomoto K
    Cell Immunol; 1989 May; 120(2):460-9. PubMed ID: 2785862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
    Mazumder A; Rosenberg SA
    J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
    Saijo N; Ozaki A; Sakurai M; Ishihara J; Takahashi H; Sasaki Y; Hoshi A; Hamburger AW
    Jpn J Cancer Res; 1986 May; 77(5):487-93. PubMed ID: 3089980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimetastatic effect of recombinant human macrophage-colony-stimulating factor against lung and liver metastatic B16 melanoma.
    Sakurai T; Yamada M; Simamura S; Motoyoshi K
    Cancer Immunol Immunother; 1997 Mar; 44(1):48-54. PubMed ID: 9111584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-specific change in Dolichos biflorus lectin binding by myocardial endothelial cells during in vitro cultivation.
    Plendl J; Hartwell L; Auerbach R
    In Vitro Cell Dev Biol; 1993 Jan; 29A(1):25-31. PubMed ID: 8444743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two populations of mouse lymphokine-activated killer cells separated by use of soybean agglutinin.
    Takano M; Okada T; Maruyama T; Harada K; Imai Y; Osawa T
    Jpn J Cancer Res; 1989 Dec; 80(12):1228-37. PubMed ID: 2516850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
    Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
    In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionation of mouse cytotoxic T cells by use of lectins.
    Yamazaki T; Imai Y; Oguchi Y; Nakano T; Osawa T
    Carbohydr Res; 1983 Aug; 120():269-81. PubMed ID: 6605191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.